<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690922</url>
  </required_header>
  <id_info>
    <org_study_id>TJXYXXW</org_study_id>
    <nct_id>NCT02690922</nct_id>
  </id_info>
  <brief_title>Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients</brief_title>
  <acronym>TCLDCWTTNDPP</acronym>
  <official_title>The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to improve the major molecular remission(MMR) rate and reduce the
      cost to treat ph(+) Acute Lymphoblastic Leukemia (ALL) by adjusting chemotherapy regimens and
      the dosage of Tyrosine Kinase Inhibitor (TKI). lower the classification of chemotherapy
      drugs, lower the side effect brought by which this would be a grateful news for the patients
      once this regimens gain a successful result, which is also the final aim of our efforts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators new therapy regimens: The investigators use dexamethasone 10mg/d(d3-d7) as
      pre-processing therapy, dasatinib 100mg (d1-d84) plus prednisone 60mg/m2 (d1-24), reduce to
      d32, as inductive treatment after inductive treatment, if the patient get major molecular
      remission, patient will get to consolidation therapy, that is methotrexate (MTX) 3g/m2 d1, if
      not, this patient would be excluded from our trail. after consolidation therapy, if the
      patient have matched bone marrow donor, the investigators will suggest the patient receipting
      allogens-stem cell transplantation, otherwise, autogens stem cell transplantation can also be
      considered once the patient have no applicable bone marrow donor. on the other side, if the
      patient still not get MMR after this two cycle, maybe the patient can try Car-T, or other
      chemotherapy regimens.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of major molecular remission after two cycle chemotherapy with MTX and dasatinib</measure>
    <time_frame>115 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time needed to achieve MMR</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>ph+ Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>ph+ ALL with dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in the arm are newly diagnosed ph+ ALL,the patient first receive dexamethasone as pretreatment,then dasatinib and prednisone are used as inductive treatment,and methotrexate to consolidate the therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>100mg (d1-d84)</description>
    <arm_group_label>ph+ ALL with dasatinib</arm_group_label>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>60mg/m2 d1-24</description>
    <arm_group_label>ph+ ALL with dasatinib</arm_group_label>
    <other_name>Pred</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>10mg/d 3-7days</description>
    <arm_group_label>ph+ ALL with dasatinib</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>3g/m2 1day</description>
    <arm_group_label>ph+ ALL with dasatinib</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Get signed the informed consent of patients and family members

          2. Age â‰¥ 18 one full year of life

          3. Confirm the ph + ALL at molecular biology level

          4. Normal heart and lungs function

          5. Normal liver and kidney function

        Exclusion Criteria:

          1. Leukemia in the nervous system

          2. Recurrent patients

          3. Allergies associated with any drug in our research

          4. At the same time with other organs' malignant tumours

          5. participating in other clinical researches at the same time
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Meng, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tongji hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests</url>
    <description>Information about reproducing this article in parts or in its entirety</description>
  </link>
  <results_reference>
    <citation>Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Akiyama H, Onishi S. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. Int J Hematol. 2014 Feb;99(2):141-53. doi: 10.1007/s12185-013-1470-1. Epub 2013 Dec 20.</citation>
    <PMID>24357015</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Meng Li</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

